Education
About Us
Working with TipRanks
Follow Us
PainReform (PRFX)
NASDAQ:PRFX
PRFX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.25 - $16.63
Previous CloseN/A
Volume49.01K
Average Volume (3M)229.17K
Market Cap
$2.82M
Enterprise Value-$1.22M
Total Cash (Recent Filing)$4.26M
Total Debt (Recent Filing)$45.00K
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,013,141
10 Day Avg. Volume319,053
30 Day Avg. Volume229,167
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit304.11
Enterprise Value/Ebitda0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
PainReform News
PremiumCompany Announcements
PainReform Expands into Ophthalmology with Strategic Investment in LayerBio
PremiumCompany Announcements
PainReform Launches AI Pilot with Econergy in Romania
PremiumCompany Announcements
PainReform Regains Nasdaq Compliance as of April 16, 2025PremiumCompany Announcements
PainReform Moves Towards Nasdaq Compliance with Strategic Acquisition
PremiumCompany Announcements
PainReform Shareholders Approve Key Proposals at April MeetingBulls Say, Bears Say
Bulls Say
Product EfficacyPRF-110 was found to statistically significantly reduce pain over the first 48-hours.
Bears Say
Financial NeedsPainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.22%
Mutual Funds
0.64% Other Institutional Investors
99.36% Public Companies and Individual Investors
PRFX FAQ
What was PainReform’s price range in the past 12 months?
PainReform lowest stock price was $1.25 and its highest was $16.63 in the past 12 months.
What is PainReform’s market cap?
PainReform’s market cap is $2.82M.
When is PainReform’s upcoming earnings report date?
PainReform’s upcoming earnings report date is Aug 13, 2025 which is in 26 days.
How were PainReform’s earnings last quarter?
Currently, no data Available
Is PainReform overvalued?
According to Wall Street analysts PainReform’s price is currently Overvalued.
Does PainReform pay dividends?
PainReform does not currently pay dividends.
What is PainReform’s EPS estimate?
PainReform’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainReform have?
PainReform has 2,013,141 shares outstanding.
What happened to PainReform’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PainReform?
Currently, no hedge funds are holding shares in PRFX
Company Description
PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
Evoke Pharma
―
RedHill Biopharma
―
Sunshine Biopharma
―